Biomarker Discovery and Validation: Statistical Considerations

Fang Shu Ou; Stefan Michiels; Yu Shyr; Alex A. Adjei; Ann L. Oberg

doi:10.1016/j.jtho.2021.01.1616

Biomarker Discovery and Validation: Statistical Considerations

Fang Shu Ou, Stefan Michiels, Yu Shyr, Alex A. Adjei, Ann L. Oberg

Research output: Contribution to journal › Article › peer-review

Abstract

Biomarkers have various applications including disease detection, diagnosis, prognosis, prediction of response to intervention, and disease monitoring. In this era of precision medicine, having validated biomarkers to inform clinical decision making is more important than ever. In this article, we discuss best the practices and potential issues in biomarker discovery and validation. We encourage team science partnerships to bring cutting-edge discovery from bench to bedside, leading to improved patient care and outcomes.

Original language	English (US)
Pages (from-to)	537-545
Number of pages	9
Journal	Journal of Thoracic Oncology
Volume	16
Issue number	4
DOIs	https://doi.org/10.1016/j.jtho.2021.01.1616
State	Published - Apr 2021

Keywords

Biomarker
Clinical trial
Confirmation analysis
Exploratory analysis

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.jtho.2021.01.1616

Cite this

@article{39f00214d34d4cb6bc94d3623d5214de,

title = "Biomarker Discovery and Validation: Statistical Considerations",

abstract = "Biomarkers have various applications including disease detection, diagnosis, prognosis, prediction of response to intervention, and disease monitoring. In this era of precision medicine, having validated biomarkers to inform clinical decision making is more important than ever. In this article, we discuss best the practices and potential issues in biomarker discovery and validation. We encourage team science partnerships to bring cutting-edge discovery from bench to bedside, leading to improved patient care and outcomes.",

keywords = "Biomarker, Clinical trial, Confirmation analysis, Exploratory analysis",

author = "Ou, {Fang Shu} and Stefan Michiels and Yu Shyr and Adjei, {Alex A.} and Oberg, {Ann L.}",

note = "Publisher Copyright: {\textcopyright} 2021 International Association for the Study of Lung Cancer",

year = "2021",

month = apr,

doi = "10.1016/j.jtho.2021.01.1616",

language = "English (US)",

volume = "16",

pages = "537--545",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "International Association for the Study of Lung Cancer",

number = "4",

}

TY - JOUR

T1 - Biomarker Discovery and Validation

T2 - Statistical Considerations

AU - Ou, Fang Shu

AU - Michiels, Stefan

AU - Shyr, Yu

AU - Adjei, Alex A.

AU - Oberg, Ann L.

PY - 2021/4

Y1 - 2021/4

N2 - Biomarkers have various applications including disease detection, diagnosis, prognosis, prediction of response to intervention, and disease monitoring. In this era of precision medicine, having validated biomarkers to inform clinical decision making is more important than ever. In this article, we discuss best the practices and potential issues in biomarker discovery and validation. We encourage team science partnerships to bring cutting-edge discovery from bench to bedside, leading to improved patient care and outcomes.

AB - Biomarkers have various applications including disease detection, diagnosis, prognosis, prediction of response to intervention, and disease monitoring. In this era of precision medicine, having validated biomarkers to inform clinical decision making is more important than ever. In this article, we discuss best the practices and potential issues in biomarker discovery and validation. We encourage team science partnerships to bring cutting-edge discovery from bench to bedside, leading to improved patient care and outcomes.

KW - Biomarker

KW - Clinical trial

KW - Confirmation analysis

KW - Exploratory analysis

UR - http://www.scopus.com/inward/record.url?scp=85101357100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101357100&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2021.01.1616

DO - 10.1016/j.jtho.2021.01.1616

M3 - Article

C2 - 33545385

AN - SCOPUS:85101357100

SN - 1556-0864

VL - 16

SP - 537

EP - 545

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 4

ER -

Biomarker Discovery and Validation: Statistical Considerations

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this